Jordana Daryl Kammerud
Known title: Senior Vice President & CHROCIK: 0001707582
Associated companies
Transaction History
| GLW | ▲ Buy | Option Exercise | 12,845 | $0 | 4/15/2026 | View on chart |
| GLW | ▲ Buy | Option Exercise | 5,670 | $0 | 4/15/2026 | View on chart |
| GLW | ▼ Sell | Tax Withholding | 9,018 | $1.5M | 4/15/2026 | View on chart |
| GLW | ▼ Sell | Open Market | 30,000 | $3.8M | 2/9/2026 | View on chart |
| GLW | ▼ Sell | Tax Withholding | 593 | $65K | 2/4/2026 | View on chart |
| GLW | ▲ Buy | Option Exercise | 256 | $0 | 2/4/2026 | View on chart |
| GLW | ▲ Buy | Option Exercise | 236 | $0 | 2/4/2026 | View on chart |
| GLW | ▲ Buy | Option Exercise | 101 | $0 | 2/4/2026 | View on chart |
| GLW | ▼ Sell | Other | 12,136 | $0 | 1/15/2026 | View on chart |
| GLW | ▼ Sell | Tax Withholding | 4,666 | $436K | 1/15/2026 | View on chart |
| GLW | ▼ Sell | Tax Withholding | 12,391 | $648K | 7/10/2025 | View on chart |
| GLW | ▼ Sell | Tax Withholding | 10,851 | $494K | 7/10/2024 | View on chart |
| GLW | ▲ Buy | Grant | 72,816 | $0 | 7/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Corning Faces Rating Downgrade Amid AI Risk Concerns
A recent Seeking Alpha report downgraded Corning, arguing the stock carries significant risk relative to its current valuation in the AI sector. This negative sentiment contrasts with other recent coverage highlighting Corning's new long-term deals in life sciences and its role in the growing cell culture market. The mixed narrative reflects a market weighing the company's strong fundamental partnerships against concerns about its high price-to-earnings ratio.
Corning Faces Rating Downgrade Amid AI Risk Concerns. A recent Seeking Alpha report downgraded Corning, arguing the stock carries significant risk relative to its current valuation in the AI sector. This negative sentiment contrasts with other recent coverage highlighting Corning's new long-term deals in life sciences and its role in the growing cell culture market. The mixed narrative reflects a market weighing the company's strong fundamental partnerships against concerns about its high price-to-earnings ratio.